Clinical Trial

A Study to Assess the Efficiency of Trastuzumab Deruxtecan in Russian Breast Cancer Patients

Study acronym: Traderrus
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated December 15, 2025 (before its estimated May 2026 completion). Its status may not reflect the trial's current state.
Summary
This multi-center observational retrospective study will collect real-world clinical data from eligible patients with unresectable or metastatic HER2+ breast cancer who have received one or more cycles Trastuzumab Deruxtecan in Russian Federation
Trial Details
NCT Number NCT07281001
Lead Sponsor Blokhin's Russian Cancer Research Center
Conditions HER2-positive Breast Cancer, Trastuzumab Deruxtecan
Enrollment 60 participants
Start Date 2025-12
Primary Completion 2026-05 (estimated)
Study Completion 2026-05 (estimated)
Updated on ClinicalTrials.gov 2025-12-15